Agena Bioscience’s MassARRAY® System Excels in China Ministry of Health Comparison Study of KRAS Somatic Mutation Detection Methods
contributed by Agena Bioscience |
Lianxing Yang, Ph.D. and Darryl Irwin*, Ph.D., Agena Bioscience
*Corresponding author: [email protected]
Many laboratories in China are running KRAS mutation detection assays to guide therapy selection for cancer treatment. To promote clinical KRAS mutation detection and improve the quality of laboratory testing, the National Center for Clinical Laboratories (NCCL) of the China Ministry of Health launched a KRAS External Quality Assessment project in 2014. In preparation for the project, the NCCL conducted a preliminary National KRAS Mutation Detection Inter-Lab Quality Evaluation Survey in 2013.
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!